MPMercè Pérez-Riba

Mercè Pérez-Riba

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mercè Pérez-Riba has a total of 124 co-authors. Here are the top co-authors by number of shared publications:

  • Eva Serrano-Candelas

    ProtoQSAR SL, Parque Tecnológico de Valencia, 46980 Valencia, Spain

    7 shared publications
  • Emilio Itarte

    5 shared publications
  • Sergio Martínez-Høyer

    Human Molecular Genetics Laboratory, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), Gran Via de L’Hospitalet 199, L’Hospitalet de Llobregat, 08908, Barcelona, Spain

    5 shared publications
  • Anna Aubareda

    Human Molecular Genetics Laboratory, Cell Signaling Unit, Bellvitge Biomedical Research Institute - IDIBELL, L'Hospitalet de Llobregat, Barcelona 08908, Spain

    4 shared publications
  • Jorge Grande

    Departament de Bioquímica i Biologia Molecular, Facultat de Ciències, Universitat Autònoma de Barcelona, Spain

    4 shared publications
  • Susana de la Luna

    Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain

    4 shared publications

Latest Publications

  • Open Access

    Design and synthesis of a novel non peptide CN-NFATc signaling inhibitor for tumor suppression in triple negative breast cancer

    by Adrià Sánchez-Morales, Atilla Biçer, Vasilis Panagiotopoulos, Selma Crecente-Garcia, Cristina Benaiges, Sergi Bayod, José Luís Hernández, Félix Busqué, Minos-Timotheos Matsoukas, Mercè Pérez-Riba, et al.


  • The PxIxIT motif of the RCAN3 inhibits angiogenesis and tumor progression in Triple Negative breast cancer in immunocompetent mice

    by Atilla Biçer, Patricia López-Henares, Marta Molero-Magariño, Andrea Feu-Llauradó, Miguel Sabariego-Navarro, Sergi Bayod, Laura Padilla, Mª Rosario Taco, Sara Larriba, Mercè Pérez-Riba, et al.

    RCAN proteins are endogenous regulators of the calcineurin-cytosolic nuclear factor of activated T cells (CN-NFATc) pathway that bind CN through similar conserved motifs PxIxIT and LxVP of the NFATc family. RCAN1 and RCAN3 protein levels were reported to correlate with overall survival of breast cancer patients. We additionally provided supporting results about RCAN3 role on cancer showing that overexpression of the native PxIxIT sequence of RCAN3-derived R3 peptide (PSVVVH, EGFP-R3178–210) dramatically inhibits tumor growth and tumor angiogenesis in an orthotopic mouse model of Triple Negative Breast Cancer (TNBC) in nude mice. On the other hand, RCAN3 protein and its derived peptide EGFP-R3178–210 bind to CN and inhibit NFAT-mediated cytokine gene expression without affecting CN phosphatase activity suggesting that RCAN3 and EGFP-R3178–210 peptide have tumor suppressor and immunosuppressant activity. Due to the known relationship between tumor development and immune system, as well as the relevance of CN-NFATc in the regulation of the immune system, in the present study we decided to assess the effect of EGFP-R3178–210 peptide in an orthotopic syngeneic TNBC mouse model, in order to ensure that the role of RCAN3 as immunosuppressant do not override its tumor suppressor activity. Our results evidence that EGFP-R3178–210 peptide displays an inhibitory potential on tumor growth and tumor angiogenesis similar to those obtained in the previous orthotopic TNBC model. These results highlight the importance of the RCAN3 peptide as a tumor suppressor protein and totally complement our previous results, indicating that this antitumor activity role is maintained in the presence of a complete functional immune system.


  • Open Access

    Calcineurin Undergoes a Conformational Switch Evoked via Peptidyl-Prolyl Isomerization

    by Alicia Guasch, Álvaro Aranguren-Ibáñez, Rosa Pérez-Luque, David Aparicio, Sergio Martínez-Høyer, M Carmen Mulero, Eva Serrano-Candelas, Mercè Pérez-Riba, Ignacio Fita

    A limited repertoire of PPP family of serine/threonine phosphatases with a highly conserved catalytic domain acts on thousands of protein targets to orchestrate myriad central biological roles. A major structural reorganization of human calcineurin, a ubiquitous Ser/Thr PPP regulated by calcium and calmodulin and targeted by immunosuppressant drugs cyclosporin A and FK506, is unveiled here. The new conformation involves trans- to cis- isomerization of proline in the SAPNY sequence, highly conserved across PPPs, and remodels the main regulatory site where NFATc transcription factors bind. Transitions between cis- and trans- conformations may involve peptidyl prolyl isomerases such as cyclophilin A and FKBP12, which are known to physically interact with and modulate calcineurin even in the absence of immunosuppressant drugs. Alternative conformations in PPPs provide a new perspective on interactions with substrates and other protein partners and may foster development of more specific inhibitors as drug candidates.


  • Identification of small-molecule inhibitors of calcineurin-NFATc signaling that mimic the PxIxIT motif of calcineurin binding partners

    by Minos-Timotheos Matsoukas, Álvaro Aranguren-Ibáñez, Teresa Lozano, Virginia Nunes, Juan José Lasarte, Leonardo Pardo, Mercè Pérez-Riba

    Calcineurin (CN), a serine and threonine protein phosphatase that depends on Ca2+ and calmodulin for its activity, is the target of the immunosuppressant drugs cyclosporin A (CsA) and tacrolimus (FK506). CN dephosphorylates and activates members of the NFATc (nuclear factor of activated T cells) family of transcription factors in T cells by binding to their conserved PxIxIT motif. Upon dephosphorylation, NFATc proteins translocate to the nucleus, where they stimulate the expression of genes encoding cytokines and chemokines that are required for T cell proliferation and the immune response. We performed a pharmacophore-based virtual screening of ~5.5 million commercially available, “drug-like” compounds to identify nonpeptidic compounds that inhibited the CN-dependent activation of NFATc signaling and that could serve as potential drug candidates for immunosuppressive therapy. Of 32 compounds that mimicked the PxIxIT motif, 7 competed with NFATc for binding to CN in vitro without interfering with the phosphatase activity of CN. Furthermore, in activated human CD4+ T cells, four of the seven compounds inhibited the expression of NFATc-dependent genes, cytokine production, and cell proliferation, suggesting that these may have therapeutic potential as immunosuppressive agents.


  • RCAN 1 and 3 proteins regulate thymic positive selection

    by Eva Serrano-Candelas, Germán Alemán-Muench, Sònia Solé-Sánchez, Anna Aubareda, Sergio Martínez-Høyer, Jaume Adán, Álvaro Aranguren-Ibáñez, Melanie A. Pritchard, Gloria Soldevila, Mercè Pérez-Riba


  • Open Access

    A novel role for an RCAN3-derived peptide as a tumor suppressor in breast cancer

    by Sergio Martínez-Høyer, Sònia Solé-Sánchez, Fernando Aguado, Sara Martínez-Martínez, Eva Serrano-Candelas, José Luis Hernández, Mar Iglesias, Juan Miguel Redondo, Oriol Casanovas, Ramon Messeguer, et al.

    The members of the human regulators of calcineurin (RCAN) protein family are endogenous regulators of the calcineurin (CN)-cytosolic nuclear factor of activated T-cells (NFATc) pathway activation. This function is explained by the presence of a highly conserved calcipressin inhibitor of calcineurin (CIC) motif in RCAN proteins, which has been shown to compete with NFATc for the binding to CN and therefore are able to inhibit NFATc dephosphorylation and activation by CN. Very recently, emerging roles for NFATc proteins in transformation, tumor angiogenesis and metastasis have been described in different cancer cell types. In this work, we report that the overexpression of RCAN3 dramatically inhibits tumor growth and tumor angiogenesis in an orthotopic human breast cancer model. We suggest that RCAN3 exerts these effects in a CN-dependent manner, as mutation of the CIC motif in RCAN3 abolishes the tumor suppressor effect. Moreover, the expression of the EGFP-R3178-210 peptide, spanning the CIC motif of RCAN3, is able to reproduce all the antitumor effects of RCAN3 full-length protein. Finally, we show that RCAN3 and the EGFP-R3178-210 peptide inhibit the CN-NFATc signaling pathway and the induction of the NFATc-dependent gene cyclooxygenase-2. Our work suggests that the EGFP-R3178-210 peptide possess potent tumor suppressor properties and therefore constitutes a novel lead for the development of potent and specific antitumoral agents. Moreover, we propose the targeting of the CN-NFATc pathway in the tumor cells constitutes an effective way to hamper tumor progression by impairing the paracrine network among tumor, endothelial and polymorphonucleated cells.


  • Open Access

    The Vertebrate RCAN Gene Family: Novel Insights into Evolution, Structure and Regulation

    by Eva Serrano-Candelas, Domènec Farré, Álvaro Aranguren-Ibáñez, Sergio Martínez-Høyer, Mercè Pérez-Riba

    Recently there has been much interest in the Regulators of Calcineurin (RCAN) proteins which are important endogenous modulators of the calcineurin-NFATc signalling pathway. They have been shown to have a crucial role in cellular programmes such as the immune response, muscle fibre remodelling and memory, but also in pathological processes such as cardiac hypertrophy and neurodegenerative diseases. In vertebrates, the RCAN family form a functional subfamily of three members RCAN1, RCAN2 and RCAN3 whereas only one RCAN is present in the rest of Eukarya. In addition, RCAN genes have been shown to collocate with RUNX and CLIC genes in ACD clusters (ACD21, ACD6 and ACD1). How the RCAN genes and their clustering in ACDs evolved is still unknown. After analysing RCAN gene family evolution using bioinformatic tools, we propose that the three RCAN vertebrate genes within the ACD clusters, which evolved from single copy genes present in invertebrates and lower eukaryotes, are the result of two rounds of whole genome duplication, followed by a segmental duplication. This evolutionary scenario involves the loss or gain of some RCAN genes during evolution. In addition, we have analysed RCAN gene structure and identified the existence of several characteristic features that can be involved in RCAN evolution and gene expression regulation. These included: several transposable elements, CpG islands in the 5′ region of the genes, the existence of antisense transcripts (NAT) associated with the three human genes, and considerable evidence for bidirectional promoters that regulate RCAN gene expression. Furthermore, we show that the CpG island associated with the RCAN3 gene promoter is unmethylated and transcriptionally active. All these results provide timely new insights into the molecular mechanisms underlying RCAN function and a more in depth knowledge of this gene family whose members are obvious candidates for the development of future therapies.


  • Protein kinase CK2-dependent phosphorylation of the human Regulators of Calcineurin reveals a novel mechanism regulating the calcineurin–NFATc signaling pathway

    by Sergio Martínez-Høyer, Álvaro Aranguren-Ibáñez, Javier García-García, Eva Serrano-Candelas, Jordi Vilardell, Virginia Nunes, Fernando Aguado, Baldo Oliva, Emilio Itarte, Mercè Pérez-Riba


  • Intragraft Expression of the IL-10 Gene Is Up-Regulated in Renal Protocol Biopsies with Early Interstitial Fibrosis, Tubular Atrophy, and Subclinical Rejection

    by Miguel Hueso, Estanis Navarro, Francesc Moreso, Francisco O'VAlle, Mercè Pérez-Riba, Raimundo García del Moral, Josep M. Grinyó, Daniel Serón


  • A fluorescent polarization-based assay for the identification of disruptors of the RCAN1–calcineurin A protein complex

    by M. Carme Mulero, Mar Orzáez, Joaquim Messeguer, Ángel Messeguer, Enrique Pérez-Payá, Mercè Pérez-Riba